联合双期CT影像组学与深度迁移学习模型预测不可切除结直肠癌肝转移的奥沙利铂疗效
多中心回顾性研究纳入360例不可切除结直肠癌肝转移患者,从动脉期和门静脉期CT提取影像组学与深度迁移学习特征并结合临床变量构建联合模型。联合模型在训练组、内部验证组和外部测试组的AUC分别为0.928、0.899和0.858,多数队列中优于影像组学、深度迁移学习和临床模型。
要点
- 联合模型在外部测试组AUC为0.858(95%CI 0.776-0.941),可用于早期预测不可切除CRLM的化疗反应。
- 联合模型在训练组、内部验证组和外部测试组AUC分别为0.928、0.899和0.858,多数队列中优于单一模型。
- 模型有助于早期识别非客观缓解患者,为个体化治疗规划提供无创工具。
核心结论
- 研究开发并验证了基于双期CT的联合模型,能够准确早期预测不可切除CRLM的化疗反应,有助于识别非客观缓解患者并支持个体化治疗规划。
研究设计与样本
- 多中心回顾性研究,纳入3个医疗中心的360例不可切除CRLM患者;一个中心患者随机分为训练组(n=199)和内部验证组(n=86),两个独立机构患者组成外部测试组(n=75);从动脉期和门静脉期CT图像提取影像组学和深度迁移学习特征,联合临床变量构建联合模型。
诊断标准与关键数值
- 联合模型在训练组AUC为0.928(95%CI 0.894-0.963),内部验证组AUC为0.899(95%CI 0.834-0.964),外部测试组AUC为0.858(95%CI 0.776-0.941);模型性能通过AUC、准确率、特异度、敏感度和临床效用评估。
临床应用与阅片要点
- 作者认为该联合模型可作为无创且临床可行的工具,用于早期识别非客观缓解患者,支持个体化治疗规划、指导及时调整治疗并最终改善患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate prediction of response to first-line oxaliplatin-based chemotherapy in unresectable colorectal liver metastases (CRLM) is critical for optimizing treatment strategies. This study aimed to develop and validate a dual-phase CT-based Combined model integrating radiomics, deep transfer learning (DTL), and clinical variables to enable individualized response prediction.
METHODS: In this multicenter retrospective study, 360 patients with unresectable CRLM were enrolled from three medical centers. Patients from one center were randomly divided into a training cohort (n = 199) and an internal validation cohort (n = 86), while an independent external test cohort (n = 75) was composed of patients from two separate institutions. Radiomics and DTL features were extracted from arterial and portal venous phase CT images. A Combined model was developed by integrating radiomics, DTL outputs, and clinical variables. Model performance was evaluated through AUC, accuracy, specificity, sensitivity, and clinical utility.
RESULTS: The Combined model achieved AUCs of 0.928 (95% CI: 0.894-0.963), 0.899 (95% CI: 0.834-0.964), and 0.858 (95% CI: 0.776-0.941) in the training, internal validation, and external test cohorts, respectively. It consistently outperformed the radiomics, DTL, and Clinical models in most cohorts, with favorable calibration and greater clinical benefit across decision thresholds.
CONCLUSION: We developed and validated a dual-phase CT Combined model that enables accurate early prediction of chemotherapy response in unresectable CRLM. By facilitating early identification of patients with non-objective response, this approach provides a non-invasive and clinically feasible tool to support individualized treatment planning, guide timely treatment modification, and ultimately improve patient outcomes.
引用
- Zhan G, Li Z, Liu X, et al. Combined dual-phase CT radiomics and deep transfer learning model for oxaliplatin response in unresectable colorectal liver metastases. Abdom Radiol (NY). 2025. PMID: 41251740. doi:10.1007/s00261-025-05284-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。